Tesaro

{{Short description|American pharmaceutical company}}

{{Infobox company

| name = Tesaro, Inc.

| logo = TESARO_logo.png

| type = Subsidiary

| industry = Pharmaceuticals

| fate =

| successor =

| founded = {{start date and age|2010}}, in Waltham, Massachusetts

| founder =

| defunct =

| hq_location_city =

| hq_location_country =

| key_people =

| products = Varubi

| owner =

| num_employees = 286

| num_employees_year = 2016

| parent = GSK
(2019–present)

| website = {{URL|tesarobio.com}}

}}

Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.

History

Tesaro was founded in 2010.{{cite web|url=http://www.fiercebiotech.com/special-report/tesaro |title=Tesaro |publisher=FierceBiotech |access-date=2017-02-25}} The company's first commercial product, Varubi, was approved by the FDA in October 2015.{{cite web|url=http://ir.tesarobio.com/secfiling.cfm?filingID=1558370-16-9294&CIK=1491576 |title=TESARO - Quarterly Report |website=Ir.tesarobio.com |access-date=2017-02-25}} As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.{{cite web|url=http://ir.tesarobio.com/secfiling.cfm?filingID=1558370-16-3631&CIK=1491576 |title=TESARO - Annual Report |website=Ir.tesarobio.com |access-date=2017-02-25}} The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.{{Citation |date=December 20, 2016 |title=ESARO (TSRO) Announces Priority FDA Review for Niraparib NDA |publisher=Street Insider |url=http://www.streetinsider.com/Corporate+News/TESARO+(TSRO)+Announces+Priority+FDA+Review+for+for+Niraparib+NDA/12358575.html |access-date=June 8, 2017 |url-status=bot: unknown |archive-url=https://web.archive.org/web/20161221144445/http://www.streetinsider.com/Corporate+News/TESARO+(TSRO)+Announces+Priority+FDA+Review+for+for+Niraparib+NDA/12358575.html |archive-date=December 21, 2016 }} In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.{{cite news |last1=D. Rockoff |first1=Jonathan |last2=Cimilluca |first2=Dana |date=May 31, 2017 |title=Tesaro Explores Sale |url=https://www.wsj.com/articles/tesaro-explores-sale-1496260323?tesla=y | work=Wall Street Journal |location=New York City, New York |access-date=June 1, 2017 }} On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale. On December 3, 2018, GSK announced it would acquire the company for $5.1 billion,{{cite web|url=https://uk.reuters.com/article/us-tesaro-m-a-gsk-idUKKBN1O218H|archive-url=https://web.archive.org/web/20181204174507/https://uk.reuters.com/article/us-tesaro-m-a-gsk-idUKKBN1O218H|url-status=dead|archive-date=December 4, 2018|title=GSK slides after buying cancer firm Tesaro for hefty $5.1 billion|date=3 December 2018|via=uk.reuters.com}} and the deal was completed on January 22, 2019.{{cite web|url=https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-tesaro-an-oncology-focused-biopharmaceutical-company/|title=GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company|date=22 January 2019}}

Products under development

  • Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
  • Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.{{cite web|url=http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Niraparib-Significantly-Improves-Outcome-of-Ovarian-Cancer-Patients-in-Landmark-Trial |title=2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial |publisher=ESMO |access-date=2017-02-25}}
  • TSR-042
  • TSR-022
  • Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

References

{{Reflist}}